DRKS00012751招募中未知
A Placebo-Controlled, Randomized, Double-Blinded Study in a Parallel-Group Comparison to evaluate Efficacy and Safety of a Lysine Containing Dietary Food for Special Medicinal Purposes vs. Placebo for the Treatment of Herpes Labialis - LYS.HSL.02
Weber & Weber GmbH & Co. KGBiologische Arzneimittel0 个研究点目标入组 205 人开始时间: 2017年8月8日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 205
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Inclusion Criteria for the Run-in Phase
- •Subjects must meet all of the following inclusion criteria to be eligible for enrolment into the run-in phase of the trial:
- •Patients with at least 2 but not more than 4 episodes of recurrent herpes labialis in the last 12 months before the start of trial.
- •Age of the patient between 18 and 65 years
- •Written informed consent.
- •Inclusion Criteria for the Treatment Phase
- •Subjects must meet all of the following inclusion criteria to be eligible for enrolment into the treatment phase of the trial:
- •All inclusion criteria of the run-in phase have to be answered with a YES.
- •Exclusion criteria 2 - 9 of the run-in phase have to be answered with a NO
- •Patients with an acute herpes labialis for not more than 48 hours.
- •Treatment of the acute herpes labialis was initiated not later than 6 hours after the first signs of prodrome.
- •Last episode resolved at least 14 days before start of treatment
- •Affected site is restricted to the nasal and labial area
- •One single site of herpes
排除标准
- •Exclusion Criteria for the Run-in Phase
- •Subjects presenting any of the following exclusion criteria must not be included in the run-in phase of the trial:
- •Patients with an existing herpes labialis currently under treatment.
- •Patients with an existing herpes labialis not yet under treatment, but whose prodrome began more than 6 hours ago.
- •Intake of medication or supplements containing more than 1 g of L-Lysine per day during the last 14 days.
- •Medical or dermatological conditions that interfere with the treatment or assessment of the herpes lesions (e.g., eczema, psoriasis, acne, seborrhoeic dermatitis).
- •Immunosuppressive disease.
- •Systemic, severe as well as history of uncontrolled chronic disease or a concurrent clinically significant illness, or medical condition, which in the investigator’s opinion, would contraindicate study participation or compliance with protocol mandated procedures.
- •Alcohol or drug abuse.
- •Hypersensitivity to L-lysine and / or to the ingredients of the investigational nutritional supplement.
- •Simultaneous participation in another clinical trial or participation in any clinical trial involving an investigational medicinal product or nutritional product within 30 days prior to written informed consent for this trial.
- •Exclusion Criteria for the Treatment Phase
- •Subjects presenting any of the following exclusion criteria must not be included in the treatment phase of the trial:
- •Patients with multiple sites of beginning herpes.
- •Topical and / or systemic treatments for herpes (including antiviral agents, anti-inflammatory agents, analgesic agents, immunomodulating drugs) during 14 days before treatment of herpes.
- •Intake of medication or supplements containing more than 1 g of L-Lysine per day during 14 days before treatment of herpes.
研究者
相似试验
已完成
2 期
A Clinical trial to study the effect of an anti-diarrheal drug Crofelemer in patients with infectious diarrheaCTRI/2009/091/000361Glenmark Pharmaceuticals Ltd.80
进行中（未招募）
1 期
The use of ANAVEX2-73 as a new therapeutic treatment for Patients with Rett SyndromeRett SyndromeMedDRA version: 20.0Level: PTClassification code 10077709Term: Rett syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2019-004345-32-GBAnavex Germany GmbH30
尚未招募
3 期
Effect of multi strain probiotics capsule on clinical symptoms and intestinal permeability in functional abdominal bloating and distension.Functional abdominal bloating and distension according to the ROME IV criteria.Bloating, Distension, ProbioticsTCTR20220323007Berlin Pharmaceutical Industry Co., Ltd.52
未知
1 期
Japanese Phase 1 MAD studyType 2 Diabetes MellitusJPRN-jRCT2080221729Bristol-Myers K.K.40
招募中
1 期
Study to Assess the Safety, Tolerability and Pharmacokinetics Of ELVN-001 In Normal Healthy ParticipantsChronic Myeloid LeukamiaCancer - Leukaemia - Chronic leukaemiaACTRN12623000760673Enliven Therapeutics, Inc.80